

Giovanni Battista Migliori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3639503/publications.pdf>

Version: 2024-02-01

509
papers

26,494
citations

6613

79
h-index

9589

142
g-index

528
all docs

528
docs citations

528
times ranked

16901
citing authors

#	ARTICLE	IF	CITATIONS
1	Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 63, e147-e195.	5.8	916
2	WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. <i>European Respiratory Journal</i> , 2011, 38, 516-528.	6.7	718
3	Towards tuberculosis elimination: an action framework for low-incidence countries. <i>European Respiratory Journal</i> , 2015, 45, 928-952.	6.7	608
4	Interferon- γ release assays for the diagnosis of latent <i>Mycobacterium tuberculosis</i> infection: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2011, 37, 88-99.	6.7	490
5	Interferon- γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2011, 37, 100-111.	6.7	488
6	LTBI: latent tuberculosis infection or lasting immune responses to <i>M. tuberculosis</i> ? A TBNET consensus statement. <i>European Respiratory Journal</i> , 2009, 33, 956-973.	6.7	487
7	Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 621-629.	9.1	479
8	Management of latent <i>Mycobacterium tuberculosis</i> infection: WHO guidelines for low tuberculosis burden countries. <i>European Respiratory Journal</i> , 2015, 46, 1563-1576.	6.7	475
9	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet</i> , The, 2018, 392, 821-834.	13.7	452
10	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2010, 36, 1185-1206.	6.7	444
11	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. <i>PLoS Medicine</i> , 2012, 9, e1001300.	8.4	430
12	Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 2537.	7.4	417
13	Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 349-361.	9.1	385
14	Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2012, 40, 1430-1442.	6.7	346
15	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. <i>European Respiratory Journal</i> , 2013, 42, 156-168.	6.7	346
16	Scaling up interventions to achieve global tuberculosis control: progress and new developments. <i>Lancet</i> , The, 2012, 379, 1902-1913.	13.7	300
17	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e93-e142.	5.6	282
18	Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e183-e198.	9.1	281

#	ARTICLE	IF	CITATIONS
19	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. <i>European Respiratory Journal</i> , 2020, 56, 2001398.	6.7	273
20	European framework for tuberculosis control and elimination in countries with a low incidence. <i>European Respiratory Journal</i> , 2002, 19, 765-775.	6.7	268
21	Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 436-448.	9.1	246
22	Drug-resistant tuberculosis: time for visionary political leadership. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 529-539.	9.1	243
23	Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 321-338.	10.7	237
24	Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 63, 853-867.	5.8	237
25	Tuberculosis contact investigation in low prevalence countries: a European consensus. <i>European Respiratory Journal</i> , 2010, 36, 925-949.	6.7	234
26	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. <i>European Respiratory Journal</i> , 2017, 49, 1700387.	6.7	233
27	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2013, 42, 169-179.	6.7	226
28	Tuberculosis advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e34-e46.	9.1	223
29	Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. <i>European Respiratory Journal</i> , 2013, 42, 252-271.	6.7	211
30	Induced Sputum Cellularity. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 1172-1174.	5.6	199
31	Universal use of face masks for success against COVID-19: evidence and implications for prevention policies. <i>European Respiratory Journal</i> , 2020, 55, 2001260.	6.7	199
32	European Union Standards for Tuberculosis Care. <i>European Respiratory Journal</i> , 2012, 39, 807-819.	6.7	188
33	Clinical and operational value of the extensively drug-resistant tuberculosis definition. <i>European Respiratory Journal</i> , 2007, 30, 623-626.	6.7	179
34	Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. <i>Pulmonology</i> , 2020, 26, 233-240.	2.1	178
35	Tuberculosis treatment and management an update on treatment regimens, trials, new drugs, and adjunct therapies. <i>Lancet Respiratory Medicine</i> , the, 2015, 3, 220-234.	10.7	172
36	Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. <i>Pulmonology</i> , 2021, 27, 151-165.	2.1	172

#	ARTICLE	IF	CITATIONS
37	A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2009, 34, 387-393.	6.7	170
38	125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic?. <i>European Respiratory Journal</i> , 2007, 29, 423-427.	6.7	166
39	Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. <i>European Respiratory Journal</i> , 2009, 33, 871-881.	6.7	163
40	Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. <i>European Respiratory Journal</i> , 2013, 42, 785-801.	6.7	163
41	The WHO Global Tuberculosis 2021 Report "not so good news and turning the tide back to End TB. <i>International Journal of Infectious Diseases</i> , 2022, 124, S26-S29.	3.3	158
42	Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities. <i>Journal of Infectious Diseases</i> , 2012, 205, S147-S158.	4.0	154
43	Tuberculosis elimination: theory and practice in Europe. <i>European Respiratory Journal</i> , 2014, 43, 1410-1420.	6.7	148
44	Efficacy and safety of meropenem+clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. <i>European Respiratory Journal</i> , 2013, 41, 1386-1392.	6.7	145
45	Drug-Resistant Tuberculosis—Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs. <i>Journal of Infectious Diseases</i> , 2012, 205, S228-S240.	4.0	140
46	Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2016, 47, 394-402.	6.7	136
47	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2709-2712.	4.3	133
48	Standardized tuberculosis treatment outcome monitoring in Europe. <i>European Respiratory Journal</i> , 1998, 12, 505-510.	6.7	131
49	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. <i>European Respiratory Journal</i> , 2008, 31, 1155-1159.	6.7	131
50	Tuberculosis Treatment and Drug Regimens. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a017822-a017822.	6.2	131
51	Fibre types in skeletal muscles of chronic obstructive pulmonary disease patients related to respiratory function and exercise tolerance. <i>European Respiratory Journal</i> , 1997, 10, 2853-2860.	6.7	129
52	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	3.3	126
53	Bronchoalveolar Lavage Enzyme-linked Immunospot for a Rapid Diagnosis of Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 666-673.	5.6	125
54	Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. <i>European Respiratory Journal</i> , 2011, 37, 1269-1282.	6.7	116

#	ARTICLE	IF	CITATIONS
55	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1364-1374.	5.8	116
56	New drugs and perspectives for new anti-tuberculosis regimens. <i>Pulmonology</i> , 2018, 24, 86-98.	2.1	114
57	Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany. <i>Emerging Infectious Diseases</i> , 2008, 14, 1700-1706.	4.3	113
58	Tuberculosis control in prisons: current situation and research gaps. <i>International Journal of Infectious Diseases</i> , 2015, 32, 111-117.	3.3	113
59	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <i>European Respiratory Journal</i> , 2019, 54, 1901522.	6.7	113
60	Surveillance of tuberculosis in Europe. <i>European Respiratory Journal</i> , 1996, 9, 1097-1104.	6.7	111
61	Drug-resistant tuberculosis: Past, present, future. <i>Respirology</i> , 2010, 15, 413-432.	2.3	110
62	Tuberculosis control in Europe and international migration. <i>European Respiratory Journal</i> , 1994, 7, 1545-1553.	6.7	109
63	The impact of digital health technologies on tuberculosis treatment: a systematic review. <i>European Respiratory Journal</i> , 2018, 51, 1701596.	6.7	109
64	Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. <i>European Respiratory Journal</i> , 2006, 28, 31-34.	6.7	107
65	Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. <i>European Respiratory Review</i> , 2019, 28, 190035.	7.1	107
66	Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2017, 50, 1701462.	6.7	103
67	Multidrug-resistant and extensively drug-resistant <i>Mycobacterium tuberculosis</i> : epidemiology and control. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 857-871.	4.4	101
68	Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 633-647.	4.4	100
69	Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement. <i>European Respiratory Journal</i> , 2012, 40, 1081-1090.	6.7	99
70	Use of Genotype MTBDR Assay for Molecular Detection of Rifampin and Isoniazid Resistance in <i>Mycobacterium tuberculosis</i> Clinical Strains Isolated in Italy. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2485-2491.	3.9	98
71	Extensively Drug-resistant Tuberculosis, Italy and Germany. <i>Emerging Infectious Diseases</i> , 2007, 13, 780-782.	4.3	96
72	ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. <i>European Respiratory Journal</i> , 2014, 44, 811-815.	6.7	96

#	ARTICLE	IF	CITATIONS
73	Induced sputum to assess airway inflammation: a study of reproducibility. <i>Clinical and Experimental Allergy</i> , 1997, 27, 1138-1144.	2.9	93
74	On tuberculosis and COVID-19 co-infection. <i>European Respiratory Journal</i> , 2020, 56, 2002328.	6.7	93
75	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. <i>European Respiratory Journal</i> , 2016, 47, 1235-1243.	6.7	92
76	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 820-826.	10.7	92
77	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	6.7	89
78	The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?. <i>Lancet</i> , 2012, 379, 773-775.	13.7	88
79	Accuracy of Immunodiagnostic Tests for Active Tuberculosis Using Single and Combined Results: A Multicenter TBNET-Study. <i>PLoS ONE</i> , 2008, 3, e3417.	2.5	88
80	Tuberculosis management in Europe Recommendations of a Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region.. <i>European Respiratory Journal</i> , 1999, 14, 978.	6.7	87
81	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. <i>European Respiratory Journal</i> , 2021, 58, 2101786.	6.7	86
82	First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. <i>European Respiratory Journal</i> , 2016, 48, 935-938.	6.7	84
83	Point of care diagnostics for tuberculosis. <i>Pulmonology</i> , 2018, 24, 73-85.	2.1	84
84	Classifying new anti-tuberculosis drugs: rationale and future perspectives. <i>International Journal of Infectious Diseases</i> , 2017, 56, 181-184.	3.3	82
85	Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. <i>European Respiratory Journal</i> , 2019, 53, 1900391.	6.7	81
86	Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India. <i>PLoS ONE</i> , 2012, 7, e40781.	2.5	80
87	Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. <i>European Respiratory Journal</i> , 2015, 45, 25-29.	6.7	76
88	Tuberculosis elimination: where are we now?. <i>European Respiratory Review</i> , 2018, 27, 180035.	7.1	76
89	Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2016, 17, 373.	4.1	75
90	Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices. <i>European Respiratory Journal</i> , 2016, 48, 808-817.	6.7	75

#	ARTICLE	IF	CITATIONS
91	TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?. <i>European Respiratory Journal</i> , 2012, 39, 619-625.	6.7	74
92	Tuberculosis transmission between foreign- and native-born populations in the EU/EEA: a systematic review. <i>European Respiratory Journal</i> , 2014, 43, 1159-1171.	6.7	74
93	Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. <i>Clinical Infectious Diseases</i> , 2015, 61, S102-S118.	5.8	74
94	Genotype MTBDR plus : a Further Step toward Rapid Identification of Drug-Resistant Mycobacterium tuberculosis. <i>Journal of Clinical Microbiology</i> , 2008, 46, 393-394.	3.9	73
95	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. <i>European Respiratory Journal</i> , 2016, 48, 938-943.	6.7	71
96	Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India. <i>PLoS ONE</i> , 2011, 6, e28066.	2.5	71
97	Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. <i>European Respiratory Journal</i> , 2016, 47, 1758-1766.	6.7	69
98	Tuberculosis management in Europe Recommendations of a Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region.. <i>European Respiratory Journal</i> , 1999, 14, 978-992.	6.7	67
99	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2008, 31, 904-905.	6.7	67
100	Totally Drug-Resistant and Extremely Drug-Resistant Tuberculosis: The Same Disease?. <i>Clinical Infectious Diseases</i> , 2012, 54, 1379-1380.	5.8	67
101	Interferon- γ release assays for the diagnosis of active tuberculosis: sensible or silly?. <i>European Respiratory Journal</i> , 2009, 33, 1250-1253.	6.7	66
102	Monitoring Therapy Adherence of Tuberculosis Patients by using Video-Enabled Electronic Devices. <i>Emerging Infectious Diseases</i> , 2016, 22, 538-540.	4.3	66
103	Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2016, 48, 1503-1507.	6.7	66
104	New anti-tuberculosis drugs and regimens: 2015 update. <i>ERJ Open Research</i> , 2015, 1, 00010-2015.	2.6	65
105	Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States: Epidemiology, Surveillance, and Control. <i>Clinics in Chest Medicine</i> , 2009, 30, 637-665.	2.1	64
106	Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. <i>European Respiratory Journal</i> , 2016, 47, 333-336.	6.7	64
107	Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. <i>International Journal of Infectious Diseases</i> , 2021, 113, S82-S87.	3.3	64
108	Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. <i>European Respiratory Journal</i> , 2017, 49, 1602445.	6.7	63

#	ARTICLE	IF	CITATIONS
109	Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. <i>Tropical Medicine and International Health</i> , 2010, 15, 1052-1066.	2.3	62
110	Early tuberculosis treatment monitoring by Xpert [®] MTB/RIF: Figure 1â€“. <i>European Respiratory Journal</i> , 2012, 39, 1269-1271.	6.7	61
111	Digital health for the End TB Strategy: developing priority products and making them work. <i>European Respiratory Journal</i> , 2016, 48, 29-45.	6.7	61
112	New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1300-1310.	5.6	61
113	Risk factors associated with pulmonary tuberculosis. <i>Current Opinion in Pulmonary Medicine</i> , 2012, 18, 233-240.	2.6	60
114	Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. <i>European Respiratory Journal</i> , 2017, 49, 1700146.	6.7	59
115	Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. <i>European Respiratory Journal</i> , 2018, 52, 1800934.	6.7	59
116	Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1774-1780.	5.8	59
117	The definition of tuberculosis infection based on the spectrum of tuberculosis disease. <i>Breathe</i> , 2021, 17, 210079.	1.3	59
118	Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. <i>European Respiratory Journal</i> , 2012, 40, 814-822.	6.7	58
119	Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. <i>European Respiratory Journal</i> , 2013, 41, 491-494.	6.7	58
120	Recent developments in the diagnosis and management of tuberculosis. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16078.	2.6	58
121	Comparison of Two Methods of Processing Induced Sputum: Selected versus Entire Sputum. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 157, 665-668.	5.6	57
122	The World Health Organization standards for tuberculosis care and management. <i>European Respiratory Journal</i> , 2018, 51, 1800098.	6.7	57
123	Diagnosis of Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis: Current Standards and Challenges. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2008, 19, 169-172.	1.9	56
124	Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2020, 55, 1901467.	6.7	55
125	Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. <i>European Respiratory Journal</i> , 2014, 43, 289-292.	6.7	54
126	Harmonisation of TB control in the WHO European region: the history of the Wolfheze Workshops. <i>European Respiratory Journal</i> , 2011, 37, 950-959.	6.7	53

#	ARTICLE	IF	CITATIONS
127	TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?. <i>European Respiratory Journal</i> , 2011, 38, 1221-1223.	6.7	52
128	Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. <i>Journal of Thoracic Disease</i> , 2017, 9, 2093-2101.	1.4	52
129	Active case finding of tuberculosis in Europe: a Tuberculosis Network European Trials Group (TbNET) survey. <i>European Respiratory Journal</i> , 2008, 32, 1023-1030.	6.7	51
130	Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. <i>European Respiratory Journal</i> , 2019, 53, 1802184.	6.7	51
131	Nontuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs. <i>European Respiratory Journal</i> , 2017, 49, 1700374.	6.7	50
132	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 Update. <i>European Respiratory Journal</i> , 2018, 51, 1702678.	6.7	50
133	Evaluation of a New Line Probe Assay for Rapid Identification of <i>gyrA</i> Mutations in <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2928-2933.	3.2	49
134	Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. <i>Lancet, The</i> , 2020, 396, 402-411.	13.7	49
135	New diseases and old threats: lessons from tuberculosis for the COVID-19 response. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 544-545.	1.2	49
136	Tuberculosis elimination and the challenge of latent tuberculosis. <i>Presse Medicale</i> , 2017, 46, e13-e21.	1.9	48
137	Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2011, 38, 730-733.	6.7	47
138	Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. <i>European Respiratory Journal</i> , 2015, 46, 1205-1207.	6.7	47
139	WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. <i>Lancet, The</i> , 2016, 387, 2486-2487.	13.7	47
140	Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2017, 18, 341.	4.1	47
141	Economic analysis of two structured treatment and teaching programs on asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1996, 51, 313-319.	5.7	46
142	Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?. <i>European Respiratory Journal</i> , 2013, 42, 1449-1453.	6.7	46
143	Tuberculosis elimination: dream or reality? The case of Cyprus. <i>European Respiratory Journal</i> , 2014, 44, 543-546.	6.7	46
144	Non-tuberculous mycobacterial infections – A neglected and emerging problem. <i>International Journal of Infectious Diseases</i> , 2020, 92, S46-S50.	3.3	46

#	ARTICLE	IF	CITATIONS
145	Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence: Table 1. European Respiratory Journal, 2013, 42, 288-290.	6.7	45
146	Surgery and pleuro-pulmonary tuberculosis: a scientific literature review. Journal of Thoracic Disease, 2016, 8, E474-E485.	1.4	45
147	Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?. Jornal Brasileiro De Pneumologia, 2016, 42, 374-385.	0.7	45
148	COVID-19 and tuberculosis—threats and opportunities. International Journal of Tuberculosis and Lung Disease, 2020, 24, 757-760.	1.2	45
149	Improving the TB case management: the International Standards for Tuberculosis care. European Respiratory Journal, 2006, 28, 687-690.	6.7	44
150	Determinants of Stunting and Recovery from Stunting in Northwest Uganda. International Journal of Epidemiology, 1994, 23, 782-786.	1.9	43
151	Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. Emerging Infectious Diseases, 2017, 23, 1718-1721.	4.3	43
152	Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respiratory Medicine, 2006, 100, 1566-1572.	2.9	42
153	Incidence of Venous Thromboembolism in Tuberculosis Patients. Respiration, 2006, 73, 396-396.	2.6	42
154	Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. European Respiratory Journal, 2012, 40, 133-142.	6.7	42
155	Drug-resistant tuberculosis. Current Opinion in Pulmonary Medicine, 2013, 19, 266-272.	2.6	42
156	Drug Resistance in Mycobacterium tuberculosis. Chest, 2015, 147, 1135-1143.	0.8	42
157	The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. International Journal of Infectious Diseases, 2022, 124, S12-S19.	3.3	42
158	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. International Journal of Infectious Diseases, 2019, 83, 72-76.	3.3	41
159	Celebrating World Tuberculosis Day at the time of COVID-19. European Respiratory Journal, 2020, 55, 2000650.	6.7	41
160	Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC). European Respiratory Journal, 2011, 38, 493-495.	6.7	40
161	Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection. European Respiratory Journal, 2010, 36, 1242-1247.	6.7	39
162	Extensively drug-resistant tuberculosis: back to the future. European Respiratory Journal, 2010, 36, 475-477.	6.7	39

#	ARTICLE	IF	CITATIONS
163	Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Review of Anti-Infective Therapy, 2015, 13, 305-315.	4.4	39
164	Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. Journal of Thoracic Disease, 2016, 8, 2666-2671.	1.4	39
165	Applicability of the shorter "Bangladesh regimen"™ in high multidrug-resistant tuberculosis settings. International Journal of Infectious Diseases, 2017, 56, 190-193.	3.3	38
166	Proposal of an improved score method for the diagnosis of pulmonary tuberculosis in childhood in developing countries. Tubercle and Lung Disease, 1992, 73, 145-149.	2.1	37
167	GenoType MTBDR <i>sl</i> performance on clinical samples with diverse genetic background. European Respiratory Journal, 2012, 40, 690-698.	6.7	37
168	Drug resistant TB " latest developments in epidemiology, diagnostics and management. International Journal of Infectious Diseases, 2022, 124, S20-S25.	3.3	37
169	Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster. European Respiratory Journal, 2014, 43, 1563-1566.	6.7	36
170	Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. International Journal of Infectious Diseases, 2015, 32, 101-104.	3.3	36
171	Post tuberculosis treatment infectious complications. International Journal of Infectious Diseases, 2020, 92, S41-S45.	3.3	36
172	Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. Clinical Infectious Diseases, 2008, 46, 958-959.	5.8	35
173	Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice. European Respiratory Journal, 2016, 48, 1571-1581.	6.7	35
174	Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2017, 49, 688-694.	2.5	35
175	Different disease, same challenges: Social determinants of tuberculosis and COVID-19. Pulmonology, 2021, 27, 338-344.	2.1	35
176	WHO strategies for the programmatic management of drug-resistant tuberculosis. Expert Review of Respiratory Medicine, 2016, 10, 991-1002.	2.5	34
177	Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees. European Respiratory Journal, 2016, 47, 1345-1347.	6.7	34
178	Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 2016, 62, 1188.2-1190.	5.8	34
179	The history and evolution of immigration medical screening for tuberculosis. Expert Review of Anti-Infective Therapy, 2013, 11, 137-146.	4.4	33
180	Bacille Calmette-Guerin vaccination: the current situation in Europe. European Respiratory Journal, 2014, 43, 24-35.	6.7	33

#	ARTICLE	IF	CITATIONS
181	Mask wearing to complement social distancing and save lives during COVID-19. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 556-558.	1.2	33
182	Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. <i>European Respiratory Journal</i> , 2014, 44, 1412-1417.	6.7	32
183	ERS/WHO Tuberculosis Consilium: reporting of the initial 10 cases. <i>European Respiratory Journal</i> , 2014, 43, 286-289.	6.7	32
184	Compassionate and optimum use of new tuberculosis drugs. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1131-1132.	9.1	32
185	Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases. <i>European Respiratory Journal</i> , 2017, 50, 1700648.	6.7	32
186	Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2021, 113, S96-S99.	3.3	32
187	Anthropometry and childhood mortality in northwest and southwest Uganda.. <i>American Journal of Public Health</i> , 1993, 83, 1616-1618.	2.7	31
188	Managing latent tuberculosis infection and tuberculosis in children. <i>Pulmonology</i> , 2018, 24, 106-114.	2.1	31
189	MDR-TB and XDR-TB: drug resistance and treatment outcomes. <i>European Respiratory Journal</i> , 2009, 34, 778-779.	6.7	30
190	Tuberculosis on the move. <i>Lancet</i> , The, 2010, 375, 2127-2129.	13.7	30
191	History of Tuberculosis and Drug Resistance. <i>New England Journal of Medicine</i> , 2013, 368, 88-90.	27.0	30
192	The European Union standards for tuberculosis care: do they need an update?. <i>European Respiratory Journal</i> , 2014, 43, 933-942.	6.7	30
193	The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis. <i>European Respiratory Journal</i> , 2016, 48, 963-971.	6.7	30
194	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. <i>Journal of Infection</i> , 2019, 78, 35-39.	3.3	30
195	The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines. <i>European Respiratory Journal</i> , 2019, 54, 1901272.	6.7	30
196	Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. <i>Pulmonology</i> , 2021, 27, 403-412.	2.1	30
197	Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 700-705.	1.2	29
198	Comparison of tuberculosis surveillance systems in low-incidence industrialised countries. <i>European Respiratory Journal</i> , 2008, 32, 1616-1624.	6.7	28

#	ARTICLE	IF	CITATIONS
199	Facing multi-drug resistant tuberculosis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 144-148.	2.6	28
200	Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. <i>European Respiratory Journal</i> , 2016, 48, 1527-1529.	6.7	28
201	Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area. <i>European Respiratory Journal</i> , 2019, 53, 1802077.	6.7	28
202	Tuberculosis in the time of COVID-19: quality of life and digital innovation. <i>European Respiratory Journal</i> , 2020, 56, 2001998.	6.7	28
203	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. <i>European Respiratory Journal</i> , 2016, 48, 1160-1170.	6.7	27
204	Cross-border collaboration for improved tuberculosis prevention and care: policies, tools and experiences. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 727-736.	1.2	27
205	Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180324.	0.7	27
206	Breaking the barriers: Migrants and tuberculosis. <i>Presse Medicale</i> , 2017, 46, e5-e11.	1.9	26
207	Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey. <i>Jornal Brasileiro De Pneumologia</i> , 2017, 43, 380-392.	0.7	26
208	Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries. <i>International Journal of Infectious Diseases</i> , 2020, 92, S60-S68.	3.3	26
209	Is multidrug-resistant tuberculosis on the rise in Mozambique? Results of a national drug resistance survey. <i>European Respiratory Journal</i> , 2011, 38, 222-224.	6.7	25
210	Efficacy and tolerability of ethionamide versus prothionamide: a systematic review. <i>European Respiratory Journal</i> , 2016, 48, 946-952.	6.7	25
211	Target regimen profiles for treatment of tuberculosis: a WHO document. <i>European Respiratory Journal</i> , 2017, 49, 1602352.	6.7	25
212	Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015. <i>European Respiratory Journal</i> , 2017, 49, 1602309.	6.7	25
213	Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	25
214	Multidrug and Extensively Drug-resistant Tuberculosis. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 1063-1085.	5.1	25
215	Functional impairment during post-acute COVID-19 phase: Preliminary finding in 56 patients. <i>Pulmonology</i> , 2021, 27, 452-455.	2.1	25
216	The need for pulmonary rehabilitation following tuberculosis treatment. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 720-722.	1.2	25

#	ARTICLE	IF	CITATIONS
217	Presenting the European Forum for TB Innovation: innovative thinking in progressing towards TB elimination in Europe: Table 1. <i>European Respiratory Journal</i> , 2012, 40, 806-808.	6.7	24
218	Untreatable tuberculosis: is surgery the answer?. <i>European Respiratory Journal</i> , 2015, 45, 577-582.	6.7	24
219	Evolution of Programmatic Definitions Used in Tuberculosis Prevention and Care. <i>Clinical Infectious Diseases</i> , 2019, 68, 1787-1789.	5.8	24
220	On linezolid efficacy and tolerability. <i>European Respiratory Journal</i> , 2012, 39, 770-772.	6.7	23
221	Tuberculosis elimination, patients' lives and rational use of new drugs: revisited. <i>European Respiratory Journal</i> , 2016, 47, 664-667.	6.7	23
222	Diabetes is Associated With Severe Adverse Events in Multidrug-Resistant Tuberculosis. <i>Archivos De Bronconeumologia</i> , 2017, 53, 245-250.	0.8	23
223	La diabetes se asocia con reacciones adversas graves en la tuberculosis multirresistente. <i>Archivos De Bronconeumologia</i> , 2017, 53, 245-250.	0.8	23
224	Latent tuberculosis infection in transplant candidates: a systematic review and meta-analysis on TST and IGRA. <i>Infection</i> , 2019, 47, 353-361.	4.7	23
225	Development of a standardised tool to survey MDR-/XDR-TB case management in Europe. <i>European Respiratory Journal</i> , 2010, 36, 208-211.	6.7	22
226	Multidrug-resistant tuberculosis in Eastern Europe: still on the increase?. <i>European Respiratory Journal</i> , 2012, 39, 1290-1291.	6.7	22
227	Advancing global programmatic management of latent tuberculosis infection for at risk populations. <i>European Respiratory Journal</i> , 2016, 47, 1327-1330.	6.7	22
228	Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?. <i>International Journal of Infectious Diseases</i> , 2017, 56, 30-33.	3.3	22
229	European policies in the management of tuberculosis among migrants. <i>International Journal of Infectious Diseases</i> , 2017, 56, 85-89.	3.3	22
230	Tuberculosis control, and the where and why of artificial intelligence. <i>ERJ Open Research</i> , 2017, 3, 00056-2017.	2.6	22
231	Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients. <i>European Respiratory Journal</i> , 2019, 54, 1800353.	6.7	22
232	Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 713-722.	5.6	22
233	High Rate of Hypothyroidism in Multidrug-Resistant Tuberculosis Patients Co-Infected with HIV in Mumbai, India. <i>PLoS ONE</i> , 2013, 8, e78313.	2.5	22
234	Validation of the surveillance system for new cases of tuberculosis in a province of Northern Italy. <i>European Respiratory Journal</i> , 1995, 8, 1252-1258.	6.7	21

#	ARTICLE	IF	CITATIONS
235	European framework to decrease the burden of TB/HIV. <i>European Respiratory Journal</i> , 2004, 24, 493-501.	6.7	21
236	Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso. <i>BMC Infectious Diseases</i> , 2009, 9, 142.	2.9	21
237	Preventing and managing antimicrobial resistance: imperative for chest physicians. <i>European Respiratory Journal</i> , 2011, 37, 978-981.	6.7	21
238	Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending. <i>European Respiratory Journal</i> , 2015, 45, 317-321.	6.7	21
239	Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. <i>European Respiratory Journal</i> , 2017, 50, 1701414.	6.7	21
240	Multi and extensively drug-resistant pulmonary tuberculosis. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 244-252.	2.6	21
241	Challenging MDR-TB clinical problems – The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. <i>International Journal of Infectious Diseases</i> , 2019, 80, S68-S72.	3.3	21
242	Shortened tuberculosis treatment regimens: what is new?. <i>Jornal Brasileiro De Pneumologia</i> , 2020, 46, e20200009-e20200009.	0.7	21
243	Drug-resistant tuberculosis among foreign-born persons in Italy: Table 1. <i>European Respiratory Journal</i> , 2012, 40, 497-500.	6.7	20
244	Future directions for the ERS: Presidential plans. <i>European Respiratory Journal</i> , 2013, 42, 875-880.	6.7	20
245	The role of eHealth and mHealth in tuberculosis and tobacco control: a WHO/ERS consultation. <i>European Respiratory Journal</i> , 2015, 46, 307-311.	6.7	20
246	Roadmap for tuberculosis elimination in Latin American and Caribbean countries: a strategic alliance. <i>European Respiratory Journal</i> , 2016, 48, 1282-1287.	6.7	20
247	Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2017, 49, 1600993.	6.7	20
248	Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients. <i>International Journal of Infectious Diseases</i> , 2020, 92, S10-S14.	3.3	20
249	Tuberculosis in Europe: a problem of drug resistance or much more?. <i>Expert Review of Respiratory Medicine</i> , 2010, 4, 189-200.	2.5	19
250	Multidrug-resistant tuberculosis today. <i>Bulletin of the World Health Organization</i> , 2012, 90, 78-78.	3.3	19
251	Treatment of tuberculosis: have we turned the corner?. <i>Lancet, The</i> , 2012, 380, 955-957.	13.7	19
252	Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. <i>European Respiratory Journal</i> , 2015, 45, 287-289.	6.7	19

#	ARTICLE	IF	CITATIONS
253	Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium. <i>International Journal of Infectious Diseases</i> , 2015, 32, 156-160.	3.3	19
254	Preventing and controlling tuberculosis among refugees in Europe: more is needed. <i>European Respiratory Journal</i> , 2016, 48, 272-274.	6.7	19
255	Low paediatric tuberculosis case detection rate in Southern Mozambique. <i>European Respiratory Journal</i> , 2016, 47, 1003-1005.	6.7	19
256	World TB Day 2017: Advances, Challenges and Opportunities in the "End-TB" Era. <i>International Journal of Infectious Diseases</i> , 2017, 56, 1-5.	3.3	19
257	Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond. <i>Pulmonology</i> , 2018, 24, 132-141.	2.1	19
258	Tuberculosis in the European Union and European Economic Area: a survey of national tuberculosis programmes. <i>European Respiratory Journal</i> , 2018, 52, 1801449.	6.7	19
259	Risk Factors for Tuberculosis in Foreign-Born People (FBP) in Italy: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e94728.	2.5	19
260	Changes in sputum composition during 15min of sputum induction in healthy subjects and patients with asthma and chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2007, 101, 1543-1548.	2.9	18
261	Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 1.	2.6	18
262	Tuberculosis elimination: a dream or a reality? The case of Oman. <i>European Respiratory Journal</i> , 2018, 51, 1702027.	6.7	18
263	Management and outcomes of post-acute COVID-19 patients in Northern Italy. <i>European Journal of Internal Medicine</i> , 2020, 78, 159-160.	2.2	18
264	Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. <i>Pulmonology</i> , 2021, 27, 248-256.	2.1	18
265	Global TB Network: working together to eliminate tuberculosis. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 347-349.	0.7	18
266	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, S90-S103.	3.3	18
267	Tuberculosis and HIV infection association in a rural district of northern Uganda: epidemiological and clinical considerations. <i>Tubercle and Lung Disease</i> , 1992, 73, 285-290.	2.1	17
268	Survey of tuberculosis drug resistance among Tibetan refugees in India. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 655-662.	1.2	17
269	Recommendations for treating children with drug-resistant tuberculosis. <i>Pharmacological Research</i> , 2016, 105, 176-182.	7.1	17
270	Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration. <i>European Respiratory Journal</i> , 2016, 47, 686-688.	6.7	17

#	ARTICLE	IF	CITATIONS
271	Impact of the COVID-19 pandemic on tuberculosis services. <i>Pulmonology</i> , 2022, 28, 210-219.	2.1	17
272	Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. <i>Jornal Brasileiro De Pneumologia</i> , 0, , e20210384.	0.7	17
273	Bronchoalveolar lavage causes decrease in PaO ₂ , increase in (A- \dot{V}) gradient value and bronchoconstriction in asthmatics. <i>Respiratory Medicine</i> , 1998, 92, 191-197.	2.9	16
274	Of Blind Men and Elephants: Making Sense of Extensively Drug-resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 1000-1001.	5.6	16
275	Exploring the immune response against <i>Mycobacterium tuberculosis</i> for a better diagnosis of the infection. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2009, 57, 425-433.	2.3	16
276	Is tuberculosis elimination a reality?. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 364-365.	9.1	16
277	Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1601612.	6.7	16
278	Adolescents and young adults: a neglected population group for tuberculosis surveillance. <i>European Respiratory Journal</i> , 2018, 51, 1800176.	6.7	16
279	How to demystify COVID-19 and reduce social stigma. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 640-642.	1.2	16
280	Diagnostic Accuracy of Rapid Antigen Tests for COVID-19 Detection: A Systematic Review With Meta-analysis. <i>Frontiers in Medicine</i> , 2022, 9, 870738.	2.6	16
281	The European Respiratory Society plans its future: the 2013-2018 strategic plan. <i>European Respiratory Journal</i> , 2014, 43, 927-932.	6.7	15
282	Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. <i>European Respiratory Journal</i> , 2015, 45, 1170-1173.	6.7	15
283	Towards tackling tuberculosis in vulnerable groups in the European Union: the E-DETECT TB consortium. <i>European Respiratory Journal</i> , 2018, 51, 1702604.	6.7	15
284	Effectiveness of interventions for reducing TB incidence in countries with low TB incidence: a systematic review of reviews. <i>European Respiratory Review</i> , 2019, 28, 180107.	7.1	15
285	Prioritising children and adolescents in the tuberculosis response of the WHO European Region. <i>European Respiratory Review</i> , 2019, 28, 180106.	7.1	15
286	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <i>Frontiers in Medicine</i> , 2020, 7, 572485.	2.6	15
287	Risk factors for early mortality in patients with pulmonary tuberculosis admitted to the emergency room. <i>Pulmonology</i> , 2021, 27, 35-42.	2.1	15
288	Tuberculosis and COVID-19, the new cursed duet: what differs between Brazil and Europe?. <i>Jornal Brasileiro De Pneumologia</i> , 2021, 47, 20210044.	0.7	15

#	ARTICLE	IF	CITATIONS
289	Update in Tuberculosis and Nontuberculous Mycobacterial Disease 2010. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 180-185.	5.6	14
290	Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is "blind" treatment dangerous?. European Respiratory Journal, 2011, 37, 1283-1285.	6.7	14
291	Key role of tuberculosis services funding mechanisms in tuberculosis control and elimination. European Respiratory Journal, 2015, 45, 289-291.	6.7	14
292	Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis. Medicine (United States), 2016, 95, e5347.	1.0	14
293	Reversing the tuberculosis upwards trend: a success story in Romania. European Respiratory Journal, 2009, 33, 168-170.	6.7	13
294	The ERS Research Agency: the beginning. European Respiratory Journal, 2016, 47, 1017-1023.	6.7	13
295	De-isolation of patients with pulmonary tuberculosis after start of treatment "clear, unequivocal guidelines are missing. International Journal of Infectious Diseases, 2017, 56, 34-38.	3.3	13
296	The long and winding road of chest radiography for tuberculosis detection. European Respiratory Journal, 2017, 49, 1700364.	6.7	13
297	Diagnostic performances of the Xpert MTB/RIF in Brazil. Respiratory Medicine, 2018, 134, 12-15.	2.9	13
298	Causal inference with multiple concurrent medications: A comparison of methods and an application in multidrug-resistant tuberculosis. Statistical Methods in Medical Research, 2019, 28, 3534-3549.	1.5	13
299	Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?. International Journal of Infectious Diseases, 2020, 92, S5-S9.	3.3	13
300	Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998-2000. European Respiratory Journal, 2003, 21, 129-134.	6.7	12
301	Unmasking tuberculosis in the era of antiretroviral treatment. European Respiratory Journal, 2012, 39, 1064-1075.	6.7	12
302	Paediatric tuberculosis in Europe: lessons from Denmark and inclusive strategies to consider. European Respiratory Journal, 2014, 43, 678-684.	6.7	12
303	Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLoS ONE, 2016, 11, e0151724.	2.5	12
304	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. European Respiratory Journal, 2016, 47, 1288-1290.	6.7	12
305	Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives. European Respiratory Journal, 2017, 50, 1701632.	6.7	12
306	Rediscovering high technology from the past: thoracic surgery is back on track for multidrug-resistant tuberculosis. Expert Review of Anti-Infective Therapy, 2012, 10, 1109-1115.	4.4	11

#	ARTICLE	IF	CITATIONS
307	Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil. <i>Revista Portuguesa De Pneumologia</i> , 2016, 22, 337-341.	0.7	11
308	Recommendations Concerning the First-Line Treatment of Children with Tuberculosis. <i>Paediatric Drugs</i> , 2016, 18, 13-23.	3.1	11
309	Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries. <i>European Respiratory Journal</i> , 2017, 49, 1602242.	6.7	11
310	Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data. <i>Revista Portuguesa De Pneumologia</i> , 2017, 23, 27-30.	0.7	11
311	Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2020, 55, 1901908.	6.7	11
312	Practices of therapeutic drug monitoring in tuberculosis: an international survey. <i>European Respiratory Journal</i> , 2022, 59, 2102787.	6.7	11
313	Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 879-883.	3.0	10
314	Defining priorities: swine-origin H1N1 and the MDR-TB epidemic. <i>Lancet, The</i> , 2009, 373, 2108.	13.7	10
315	Finding the way through the respiratory symptoms jungle: PAL can help: Respiratory Infections Assembly contribution to the celebration of 20 years of the ERS. <i>European Respiratory Journal</i> , 2010, 36, 979-982.	6.7	10
316	Tuberculosis and HIV co-infection: do we have a surveillance system in Europe?: Table 1. <i>European Respiratory Journal</i> , 2011, 38, 1258-1260.	6.7	10
317	Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy: Figure 1. <i>European Respiratory Journal</i> , 2012, 39, 1263-1266.	6.7	10
318	Management of drug resistant TB in patients with HIV co-infection. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2737-2750.	1.8	10
319	Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , 2017, 5, 159-161.	10.7	10
320	Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis. <i>Lancet Infectious Diseases</i> , 2018, 18, 480-481.	9.1	10
321	Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico. <i>European Respiratory Journal</i> , 2018, 51, 1702267.	6.7	10
322	Eliminating tuberculosis in Latin America: making it the point. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 73-76.	0.7	10
323	Multidrug-resistant tuberculosis. <i>Lancet, The</i> , 2019, 394, 298.	13.7	10
324	Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2020, 26, .	4.3	10

#	ARTICLE	IF	CITATIONS
325	Tuberculosis and its future in the COVID-19 era: The Pulmonology series 2021. <i>Pulmonology</i> , 2021, 27, 94-96.	2.1	10
326	A snapshot of exhaled nitric oxide and asthma characteristics: experience from high to low income countries. <i>Pulmonology</i> , 2022, 28, 44-58.	2.1	10
327	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20220087.	0.7	10
328	Cost-Effectiveness Analysis of Invasive and Noninvasive Tests in High Risk Patients Treated With Amiodarone After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1481-1489.	2.8	9
329	Availability of anti-tuberculosis drugs in Europe: Table 1. <i>European Respiratory Journal</i> , 2012, 40, 500-503.	6.7	9
330	Do we need a new Fleming Époque: The nightmare of drug-resistant tuberculosis. <i>International Journal of Mycobacteriology</i> , 2013, 2, 123-125.	0.6	9
331	Toward Tuberculosis Elimination in Low-Incidence Countries: Reflections From a Global Consultation. <i>Annals of Internal Medicine</i> , 2014, 161, 670.	3.9	9
332	The challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: a report of three cases. <i>Jornal Brasileiro De Pneumologia</i> , 2015, 41, 554-559.	0.7	9
333	Automated Digital Microscopy in New Tuberculosis Diagnostic Algorithms. Can It Boost Case Finding?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1352-1353.	5.6	9
334	Numbers needed to treat to prevent tuberculosis. <i>European Respiratory Journal</i> , 2015, 46, 1838-1839.	6.7	9
335	How to manage children who have come into contact with patients affected by tuberculosis. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2015, 1, 1-12.	1.3	9
336	Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 898.	9.1	9
337	Genotypic and phenotypic <i>M. tuberculosis</i> resistance: guiding clinicians to prescribe the correct regimens. <i>European Respiratory Journal</i> , 2017, 50, 1702292.	6.7	9
338	Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 – Wanted: Leaders for a TB-Free World. You can make history. End TB. <i>International Journal of Infectious Diseases</i> , 2018, 68, 122-124.	3.3	9
339	Recent evidence on delamanid use for rifampicin-resistant tuberculosis. <i>Journal of Thoracic Disease</i> , 2019, 11, S457-S460.	1.4	9
340	Tuberculosis series 2020. <i>Jornal Brasileiro De Pneumologia</i> , 2020, 46, e20200027-e20200027.	0.7	9
341	History of prevention, diagnosis, treatment and rehabilitation of pulmonary sequelae of tuberculosis. <i>Presse Medicale</i> , 2022, 51, 104112.	1.9	9
342	Multidrug- and extensively drug-resistant TB in persons living with HIV. <i>Expert Review of Respiratory Medicine</i> , 2009, 3, 245-254.	2.5	8

#	ARTICLE	IF	CITATIONS
343	XDR tuberculosis in South Africa: old questions, new answers. <i>Lancet, The</i> , 2010, 375, 1760-1761.	13.7	8
344	ERJ peer reviewers: does this pillar of the Journal's quality need help?. <i>European Respiratory Journal</i> , 2011, 38, 251-252.	6.7	8
345	Measuring the effect of tuberculosis control: a step forward. <i>Lancet, The</i> , 2014, 383, 2026-2028.	13.7	8
346	Predicting the effect of improved socioeconomic health determinants on the tuberculosis epidemic. <i>The Lancet Global Health</i> , 2018, 6, e475-e476.	6.3	8
347	Hoja de ruta para la eliminaci3n de la tuberculosis en Latinoam3rica y el Caribe. <i>Archivos De Bronconeumologia</i> , 2018, 54, 7-9.	0.8	8
348	Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2734.	2.5	8
349	TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia. <i>Journal of Infection in Developing Countries</i> , 2013, 7, 289-292.	1.2	8
350	The multidrug-resistant tuberculosis threat: old problems and new solutions. <i>Journal of Thoracic Disease</i> , 2015, 7, E354-60.	1.4	8
351	A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium. <i>Journal of Thoracic Disease</i> , 2015, 7, 1080-5.	1.4	8
352	War in Ukraine: an immense threat to the fight against tuberculosis. <i>European Respiratory Journal</i> , 2022, 59, 2200493.	6.7	8
353	Conditioned inhibition of antibody response and CD4 positive cells. <i>Physiology and Behavior</i> , 1998, 64, 395-398.	2.1	7
354	Prospective multicentre study on the evaluation of antituberculosis treatment results in Italy: comparison of the culture- versus the smear-based methods. <i>European Respiratory Journal</i> , 1999, 13, 900.	6.7	7
355	<i>Mycobacterium tuberculosis</i> Complex Drug Resistance in Italy. <i>Emerging Infectious Diseases</i> , 2004, 10, 752-753.	4.3	7
356	Ripped from the headlines: how can we harness communications to control TB?. <i>European Respiratory Journal</i> , 2007, 30, 194-198.	6.7	7
357	Tuberculosis, one disease, many faces. <i>Monaldi Archives for Chest Disease</i> , 2008, 69, 2-4.	0.6	7
358	Drug resistance and tuberculosis elimination in low-incidence countries. <i>European Respiratory Journal</i> , 2014, 44, 1408-1411.	6.7	7
359	New effective antituberculosis regimens. <i>Lancet, The</i> , 2015, 385, 1703-1704.	13.7	7
360	Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care. <i>European Respiratory Journal</i> , 2016, 48, 1278-1281.	6.7	7

#	ARTICLE	IF	CITATIONS
361	Recommendations Concerning the Therapeutic Approach to Immunocompromised Children With Tuberculosis. <i>Clinical Therapeutics</i> , 2016, 38, 180-190.	2.5	7
362	Effectiveness of pulmonary rehabilitation in severe asthma: a retrospective data analysis. <i>Journal of Asthma</i> , 2020, 57, 1365-1371.	1.7	7
363	Factors contributing to drug-resistant tuberculosis treatment outcome in five countries in the Eastern Europe and Central Asia region. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.6	7
364	Time course of exercise capacity in patients recovering from COVID-19-associated pneumonia. <i>Jornal Brasileiro De Pneumologia</i> , 2021, 47, e20210076.	0.7	7
365	Tuberculosis series. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 71-72.	0.7	7
366	Global reporting on tuberculosis preventive treatment among contacts. <i>European Respiratory Journal</i> , 2022, 59, 2102753.	6.7	7
367	Consensus Not Yet Reached on Key Drugs for Extensively Drug-Resistant Tuberculosis Treatment. <i>Clinical Infectious Diseases</i> , 2009, 49, 315-316.	5.8	6
368	Clinical trials: registration and transparency. <i>European Respiratory Journal</i> , 2016, 47, 1342-1344.	6.7	6
369	World TB Day 2016: reflections on the global TB emergency. <i>Lancet Respiratory Medicine</i> , 2016, 4, 249-251.	10.7	6
370	Standard operating procedures for tuberculosis care. <i>European Respiratory Journal</i> , 2017, 49, 1700515.	6.7	6
371	Bedaquiline: how better to use it. <i>European Respiratory Journal</i> , 2017, 50, 1701670.	6.7	6
372	Estrategias de la OMS para el tratamiento de la tuberculosis resistente. <i>Archivos De Bronconeumologia</i> , 2017, 53, 95-97.	0.8	6
373	Roadmap for Tuberculosis Elimination in Latin America and the Caribbean. <i>Archivos De Bronconeumologia</i> , 2018, 54, 7-9.	0.8	6
374	The European Respiratory Society's 10 Principles for Lung Health. <i>European Respiratory Journal</i> , 2018, 52, 1801373.	6.7	6
375	Research Needs on Respiratory Health in Migrant and Refugee Populations. An Official American Thoracic Society and European Respiratory Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1247-1255.	3.2	6
376	Commemorating World TB Day 2020: "It's TIME" It's time to End the Global TB Epidemic. <i>International Journal of Infectious Diseases</i> , 2020, 92, S1-S4.	3.3	6
377	Pulmonary tuberculosis in intensive care setting, with a focus on the use of severity scores, a multinational collaborative systematic review. <i>Pulmonology</i> , 2022, 28, 297-309.	2.1	6
378	Post-tuberculosis lung disease: a comparison of Brazilian, Italian, and Mexican cohorts. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20210515.	0.7	6

#	ARTICLE	IF	CITATIONS
379	DOTS implementation in a post-war, United Nations-administered territory: Lessons from Kosovo. <i>Respiratory Medicine</i> , 2008, 102, 121-127.	2.9	5
380	Searching for the Tuberculosis "Needle in the Haystack". <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 916-917.	5.6	5
381	The European Respiratory Journal targets tuberculosis. <i>European Respiratory Journal</i> , 2010, 36, 714-715.	6.7	5
382	TB or not TB: update from the ERS Respiratory Infection Assembly 10. <i>European Respiratory Journal</i> , 2010, 36, 665-670.	6.7	5
383	Interferon- γ release assays for diagnosis of active pleural tuberculosis: a developing world perspective. <i>European Respiratory Journal</i> , 2011, 38, 747-748.	6.7	5
384	Lessons learnt in Europe on tuberculosis surveillance, outbreaks and BCG vaccination in 2011. <i>European Respiratory Journal</i> , 2013, 41, 767-771.	6.7	5
385	Results of a tuberculin skin testing survey in Albania. <i>Journal of Infection in Developing Countries</i> , 2014, 8, 310-314.	1.2	5
386	Extra-pulmonary tuberculosis: the comorbidity of the near future?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 1389-1389.	1.2	5
387	Bedaquiline: finding the pores on the pot. <i>European Respiratory Journal</i> , 2015, 46, 289-291.	6.7	5
388	Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?. <i>European Respiratory Journal</i> , 2016, 48, 1230-1233.	6.7	5
389	New anti-tuberculosis drugs for special populations: a difficult-to-address issue. <i>European Respiratory Journal</i> , 2016, 48, 957-958.	6.7	5
390	WHO Strategies for the Management of Drug-Resistant Tuberculosis. <i>Archivos De Bronconeumologia</i> , 2017, 53, 95-97.	0.8	5
391	Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!. <i>EBioMedicine</i> , 2018, 29, 11-12.	6.1	5
392	International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180420.	0.7	5
393	Management and outcomes of severe childhood tuberculosis in the pediatric intensive care setting: can we identify best practices?. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20190043.	0.7	5
394	Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network. <i>Antibiotics</i> , 2021, 10, 1355.	3.7	5
395	Comparison of Tuberculin Skin test and Quantiferon immunological assay for latent Tuberculosis infection. <i>Monaldi Archives for Chest Disease</i> , 2005, 63, 158-62.	0.6	4
396	High incidence of sputum smear negative tuberculosis during HAART in Burkina Faso. <i>European Respiratory Journal</i> , 2008, 32, 1668-1669.	6.7	4

#	ARTICLE	IF	CITATIONS
397	From the authors.: European Respiratory Journal, 2010, 35, 938-940.	6.7	4
398	Xpert MTB/RIF test for tuberculosis. Lancet, The, 2011, 378, 481-482.	13.7	4
399	<i>In vitro</i> susceptibility testing and totally drug-resistant tuberculosis. European Respiratory Journal, 2013, 42, 292-292.	6.7	4
400	Cost-effectiveness of treating latent tuberculous infection: a step towards elimination? [Editorial]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1515-1515.	1.2	4
401	Monitoring predictors of mortality: A necessary action to reach TB elimination. Revista Portuguesa De Pneumologia, 2015, 21, 295-298.	0.7	4
402	Is Europe ready to reach tuberculosis elimination? An outbreak report from Southern Italy. European Respiratory Journal, 2015, 46, 274-277.	6.7	4
403	Diabetes and tuberculosis: what else beyond?. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1127-1128.	1.2	4
404	Tuberculosis management and determinants of recurrence. International Journal of Tuberculosis and Lung Disease, 2016, 20, 3-3.	1.2	4
405	Strengthening tuberculosis control to advance towards elimination: The 2018 Rev. Port. Pneumol. (RPP) TB Series. Pulmonology, 2018, 24, 67-68.	2.1	4
406	European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following new World Health Organization recommendations. European Respiratory Journal, 2018, 52, 1801617.	6.7	4
407	Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone. International Journal of Tuberculosis and Lung Disease, 2018, 22, 2-2.	1.2	4
408	TB consilia and quality of tuberculosis management. International Journal of Tuberculosis and Lung Disease, 2019, 23, 1048-1049.	1.2	4
409	Delamanid: does it have a role in tuberculosis treatment?. Lancet Respiratory Medicine,the, 2019, 7, 193-195.	10.7	4
410	Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. BMJ Open, 2020, 10, e035350.	1.9	4
411	The Role of Blood Gas Analysis in the Post-Acute Phase of COVID-19 Pneumonia. Archivos De Bronconeumologia, 2021, , .	0.8	4
412	New and repurposed drugs. , 0, , 179-204.		4
413	Tuberculosis care and control. Bulletin of the World Health Organization, 2006, 84, 428-428.	3.3	4
414	Post-tuberculosis sequelae and their socioeconomic consequences: worth investigating. The Lancet Global Health, 2021, 9, e1628-e1629.	6.3	4

#	ARTICLE	IF	CITATIONS
415	On q^2 -sets of type $(0, q^4, q^2)$ in projective planes of order $q \equiv 0 \pmod{4}$. <i>Discrete Mathematics</i> , 1994, 129, 149-158.	0.7	3
416	Microbiological confirmation of tuberculosis cases at diagnosis and at the end of treatment in Italy. <i>European Journal of Epidemiology</i> , 2000, 16, 719-724.	5.7	3
417	Performance of a lateral flow immunochromatography test for the rapid diagnosis of active tuberculosis in a large multicentre study in areas with different clinical settings and tuberculosis exposure levels. <i>Journal of Thoracic Disease</i> , 2016, 8, 3307-3313.	1.4	3
418	Better data, more tailored tuberculosis therapies. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1096-1097.	9.1	3
419	The European Respiratory Society evaluates its 2013-2018 strategic plan implementation. <i>European Respiratory Journal</i> , 2016, 47, 693-698.	6.7	3
420	Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?. <i>International Journal of Infectious Diseases</i> , 2017, 65, 133-134.	3.3	3
421	Tuberculosis, alcohol and tobacco: Dangerous liaisons. <i>Revista Portuguesa De Pneumologia</i> , 2017, 23, 177-178.	0.7	3
422	Reply to Alffenaar et al. <i>Clinical Infectious Diseases</i> , 2017, 64, 105-106.	5.8	3
423	Launching the Global TB Network. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 123-124.	1.2	3
424	World Tuberculosis Day March 24th 2019 Theme: "It's TIME" International Journal of Infectious Diseases Tuberculosis Theme Series. <i>International Journal of Infectious Diseases</i> , 2019, 80, S1-S5.	3.3	3
425	European guidance on drug-resistant tuberculosis in children and adolescents. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 9-11.	5.6	3
426	Developing health policies in patients presenting with SARS-CoV-2: consider tuberculosis. <i>The Lancet Global Health</i> , 2020, 8, e1357-e1358.	6.3	3
427	Pediatric tuberculosis in the metropolitan area of Rio de Janeiro. <i>International Journal of Infectious Diseases</i> , 2020, 98, 299-304.	3.3	3
428	Time course of exercise capacity in patients recovering from COVID-19-associated pneumonia. Authors' reply. <i>Jornal Brasileiro De Pneumologia</i> , 2021, 47, e20210328.	0.7	3
429	Tuberculosis series 2019. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20190064.	0.7	3
430	Proposal of an improved score method for the diagnosis of pulmonary tuberculosis in childhood in developing countries. <i>Tubercle and Lung Disease</i> , 1993, 74, 215.	2.1	2
431	Steps forward in LRTI and tuberculosis: update from the ERS Respiratory Infections Assembly. <i>European Respiratory Journal</i> , 2009, 33, 1448-1453.	6.7	2
432	Quantitative Pulmonary T-Cell Responses for the Diagnosis of Active Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 289-290.	5.6	2

#	ARTICLE	IF	CITATIONS
433	Tuberculosis: an ancient and evergreen disease. <i>European Respiratory Review</i> , 2011, 20, 69-70.	7.1	2
434	"Interferon- γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis." M. Sester, G. Sotgiu, C. Lange, C. Giehl, E. Girardi, G.B. Migliori, A. Bossink, K. Dheda, R. Diel, J. Dominguez, M. Lipman, J. Nemeth, P. Ravn, S. Winkler, E. Huitric, A. Sandgren and D. Manissero. <i>Eur Respir J</i> 2011; 37: 100-111.. <i>European Respiratory Journal</i> , 2012, 39, 793-793.	6.7	2
435	TB and MDR-TB: what is new in 2012?. <i>Breathe</i> , 2012, 9, 100-111.	1.3	2
436	"Interferon- γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis." R. Diel, D. Goletti, G. Ferrara, G. Bothamley, D. Cirillo, B. Kampmann, C. Lange, M. Losi, R. Markova, G.B. Migliori, A. Nienhaus, M. Ruhwald, D. Wagner, J.P. Zellweger, E. Huitric, A. Sandgren and D. Manissero. <i>Eur Respir J</i> 2011; 37: 88-99.. <i>European Respiratory Journal</i> , 2012, 39, 793-793.	6.7	2
437	Declaration on palliative care for MDR/XDR-TB [Correspondence]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 1418-1419.	1.2	2
438	Sanatoria for drug-resistant tuberculosis: an outdated response – Authors' reply. <i>Lancet</i> , The, 2012, 379, 2148-2149.	13.7	2
439	Multidrug-resistant tuberculosis in children can be treated. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 425-426.	9.1	2
440	A case of resistance beyond extensively drug-resistant tuberculosis in Japan. <i>European Respiratory Journal</i> , 2013, 42, 872-873.	6.7	2
441	Recommendations for pediatric tuberculosis vaccination in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 644-650.	3.3	2
442	Effectiveness of post-migration tuberculosis screening. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 684-685.	9.1	2
443	World TB Day 2017: Strengthening the fight against TB. <i>Presse Medicale</i> , 2017, 46, e1-e4.	1.9	2
444	Time to review treatment of isoniazid-resistant tuberculosis?. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 127-128.	9.1	2
445	Tuberculosis in the news: How do Portuguese media cover TB. <i>Pulmonology</i> , 2018, 24, 69-72.	2.1	2
446	Multidrug-resistant tuberculosis – Authors' reply. <i>Lancet</i> , The, 2019, 394, 299-300.	13.7	2
447	Digital health technology for the end TB strategy: Developing priority products and making them work. , 2016, , .		2
448	Bronchoalveolar lavage immunodiagnosis for tuberculosis suspects in Europe and Africa. <i>Thorax</i> , 2010, 65, 842-842.	5.6	1
449	Diagnosis of tuberculosis in patients with psoriasis: the need for a modified approach. <i>European Respiratory Journal</i> , 2011, 38, 232-233.	6.7	1
450	Management of MDR-TB household contacts: how difficult is it to climb the mountain? [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 1137-1138.	1.2	1

#	ARTICLE	IF	CITATIONS
451	A new paradigm for multidrug-resistant tuberculosis?. International Journal of Tuberculosis and Lung Disease, 2014, 18, 884-884.	1.2	1
452	Greek Gods and Portuguese Pneumology: implementing HERMES. Revista Portuguesa De Pneumologia, 2015, 21, 291-292.	0.7	1
453	Global Tuberculosis Elimination: The Relevance of Trend Surveillance in Mexico and Beyond. Archivos De Bronconeumologia, 2015, 51, 3-4.	0.8	1
454	Assessing tuberculosis management: what really happens to patients?. Lancet Infectious Diseases, The, 2015, 15, 1249-1251.	9.1	1
455	WHO recommendations for multidrug-resistant tuberculosis – Authors’ reply. Lancet, The, 2016, 388, 2234-2235.	13.7	1
456	TB-related mortality: a re-emerging problem in high-income countries?. International Journal of Tuberculosis and Lung Disease, 2016, 20, 428-428.	1.2	1
457	Management of extensively drug-resistant tuberculosis. Lancet Respiratory Medicine, the, 2017, 5, 237-239.	10.7	1
458	Group 5 drugs for multidrug-resistant tuberculosis: is the glass half full or half empty?. European Respiratory Journal, 2017, 49, 1602273.	6.7	1
459	Prevention of tuberculosis transmission through medical surveillance systems. Lancet Public Health, The, 2017, 2, e439-e440.	10.0	1
460	Antituberculosis Agents. , 2017, , 1264-1276.e2.		1
461	Understanding the multidrug-resistant tuberculosis epidemic in China. International Journal of Tuberculosis and Lung Disease, 2017, 21, 955-955.	1.2	1
462	Post-implementation blues: the unfulfilled potential of Xpert. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1073-1073.	1.2	1
463	Defining the best regimen to treat isoniazid-resistant tuberculosis. Lancet Respiratory Medicine, the, 2018, 6, 233-235.	10.7	1
464	Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis. European Respiratory Journal, 2018, 51, 1702187.	6.7	1
465	ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training. Breathe, 2018, 14, 269-275.	1.3	1
466	Another aetiology for tuberculosis – beyond the <i>Mycobacterium</i> . International Journal of Tuberculosis and Lung Disease, 2019, 23, 277-277.	1.2	1
467	Tuberculosis screening in outpatient healthcare workers: lessons from a high-income, low TB burden country. International Journal of Tuberculosis and Lung Disease, 2019, 23, 1024-1028.	1.2	1
468	A postgraduate qualification in tuberculosis – Message in a bottle. International Journal of Infectious Diseases, 2020, 92, S100-S102.	3.3	1

#	ARTICLE	IF	CITATIONS
469	Medical treatment of pulmonary tuberculosis. , 2013, , 11-19.		1
470	Cross-border management of tuberculosis cases through an updated ERS/WHO TB consilium. , 2015, , .		1
471	Investigating the response to COVID-19 and understanding severe TB cases: The 2022 Pulmonology TB series. Pulmonology, 2022, 28, 155-157.	2.1	1
472	FREQUENCY OF VENOUS THROMBOEMBOLISM AMONG PATIENTS WITH TUBERCULOSIS DURING SHORT-COURSE CHEMOTHERAPY. Chest, 2005, 128, 404S.	0.8	0
473	Update on clinical research of tuberculosis: a report from the European Respiratory Society. Expert Review of Respiratory Medicine, 2008, 2, 707-711.	2.5	0
474	Treatment of drug-resistant tuberculosis â€œ Authors' reply. Lancet Infectious Diseases, The, 2011, 11, 660-661.	9.1	0
475	â€œCost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russiaâ€œ Katherine Floyd, Raymond Hutubessy, Kai Kliiman, Rosella Centis, Nina Khurieva, Wieslaw Jakubowiak, Manfred Danilovits, Genadi Peremitin, Salmaan Keshavjee and Giovanni Battista Migliori. Eur Respir J 2012; 40: 133â€œ142.. European Respiratory Journal, 2012, 40, 800.1-800.	6.7	0
476	TB elimination: a dream or a reality? Key lessons from the ERS external course in Dubrovnik, Croatia. Breathe, 2013, 9, 458-461.	1.3	0
477	2012: The year in review. Part 1: Tuberculosis [Year in review]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 728-737.	1.2	0
478	Accelerating tuberculosis elimination in low-incidence settings: the role of genomics. European Respiratory Journal, 2015, 46, 1841-1843.	6.7	0
479	Long-term protectiveness of BCG. Lancet Infectious Diseases, The, 2016, 16, 140-142.	9.1	0
480	Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress. Journal of Thoracic Disease, 2017, 9, S1559-S1562.	1.4	0
481	Professor Massimo Amicosante, 1968â€œ2017. International Journal of Tuberculosis and Lung Disease, 2018, 22, 236-236.	1.2	0
482	Regimen design and pharmacokineticâ€œpharmacodynamic science: lessons learned. Lancet Infectious Diseases, The, 2019, 19, 3-4.	9.1	0
483	What is the best regimen to treat latent tuberculosis infection?. Lancet Infectious Diseases, The, 2020, 20, 263-264.	9.1	0
484	IJTLD Editorial Plan 2020â€œ2025. International Journal of Tuberculosis and Lung Disease, 2020, 24, 559-561.	1.2	0
485	Intermittent regimens for tuberculosis treatment: Back to the Future?. European Respiratory Journal, 2020, 56, 2002510.	6.7	0
486	Harnessing the energy of the corporate sector to end TB: BE health. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 21, 100206.	1.3	0

#	ARTICLE	IF	CITATIONS
487	Reply to Chang and Yew. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 778-779.	5.6	0
488	Monitoring adverse events of new drugs: a programmatic need stimulating operational research. International Journal of Tuberculosis and Lung Disease, 2020, 24, 360-361.	1.2	0
489	Rationale for Anti-Tuberculosis Chemotherapy. , 2021, , 109-120.		0
490	National Tuberculosis Strategic Planning. , 2021, , 307-318.		0
491	Tuberculosis and COVID-19 Comorbidity: A New Twenty-First-Century Cursed Duet. , 2021, , 221-227.		0
492	Tuberculosis Infection Control. , 2021, , 67-76.		0
493	Tuberculosis Series 2021. Jornal Brasileiro De Pneumologia, 2021, 47, e20210109.	0.7	0
494	What About Existing Databases?. Deutsches Ärzteblatt International, 2010, 107, 435-6; author reply 436.	0.9	0
495	Research Priorities for HIV/M. tuberculosis Co-Infection. The Open Infectious Diseases Journal, 2011, 5, 14-20.	0.6	0
496	The WHO strategy for TB control and elimination. , 2012, , 242-253.		0
497	Joint WHO/ERS initiative on e-/m-Health for TB and tobacco control. , 2015, , .		0
498	Out-patient MDR-TB care in Moldova. , 2015, , .		0
499	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis. , 2016, , .		0
500	Comparison of the accuracy of QuantiFERON TB gold in tube vs QuantiFERON-TB plus. , 2016, , .		0
501	Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis. , 2016, , .		0
502	OBSOLETE: Tuberculosis, Public Health Aspects. , 2017, , .		0
503	Bedaquiline (BQ)-containing regimen at the programmatic level for MDR-TB: preliminary results. , 2017, , .		0
504	Management of tuberculosis in the European Union: a multicentre audit. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
505	Outcomes of drug-resistant TB cases undergoing bedaquiline (BQ)-treatment and adjunctive surgery. , 2018, , .		0
506	Adapting our Journal for the new decade (and the next 100 years). International Journal of Tuberculosis and Lung Disease, 2020, 24, 268-269.	1.2	0
507	A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium. Indian Journal of Medical Research, 2017, 145, 261-263.	1.0	0
508	Commemorating World Tuberculosis Day 2022: recent <i>ERJ</i> articles of critical relevance to ending TB and saving lives. European Respiratory Journal, 2022, 59, 2200149.	6.7	0
509	Effects of COVID-19 on tuberculosis control: past, present, and future. Jornal Brasileiro De Pneumologia, 2022, 48, e20220102.	0.7	0